Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
06 2020
Historique:
received: 13 08 2019
revised: 19 01 2020
accepted: 20 01 2020
pubmed: 14 3 2020
medline: 7 1 2021
entrez: 14 3 2020
Statut: ppublish

Résumé

Histologic subtypes of malignant pleural mesothelioma are a major prognostic indicator and decision denominator for all therapeutic strategies. In an ambiguous case, a rare transitional mesothelioma (TM) pattern may be diagnosed by pathologists either as epithelioid mesothelioma (EM), biphasic mesothelioma (BM), or sarcomatoid mesothelioma (SM). This study aimed to better characterize the TM subtype from a histological, immunohistochemical, and molecular standpoint. Deep learning of pathologic slides was applied to this cohort. A random selection of 49 representative digitalized sections from surgical biopsies of TM was reviewed by 16 panelists. We evaluated BAP1 expression and CDKN2A (p16) homozygous deletion. We conducted a comprehensive, integrated, transcriptomic analysis. An unsupervised deep learning algorithm was trained to classify tumors. The 16 panelists recorded 784 diagnoses on the 49 cases. Even though a Kappa value of 0.42 is moderate, the presence of a TM component was diagnosed in 51%. In 49% of the histological evaluation, the reviewers classified the lesion as EM in 53%, SM in 33%, or BM in 14%. Median survival was 6.7 months. Loss of BAP1 observed in 44% was less frequent in TM than in EM and BM. p16 homozygous deletion was higher in TM (73%), followed by BM (63%) and SM (46%). RNA sequencing unsupervised clustering analysis revealed that TM grouped together and were closer to SM than to EM. Deep learning analysis achieved 94% accuracy for TM identification. These results revealed that the TM pattern should be classified as non-EM or at minimum as a subgroup of the SM type.

Identifiants

pubmed: 32165206
pii: S1556-0864(20)30174-X
doi: 10.1016/j.jtho.2020.01.025
pmc: PMC8864581
mid: NIHMS1723349
pii:
doi:

Substances chimiques

BAP1 protein, human 0
Tumor Suppressor Proteins 0
Ubiquitin Thiolesterase EC 3.4.19.12

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1037-1053

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Références

Nat Med. 2019 Oct;25(10):1519-1525
pubmed: 31591589
Ann Diagn Pathol. 2017 Feb;26:31-37
pubmed: 28038708
Am J Surg Pathol. 2016 May;40(5):714-8
pubmed: 26900815
J Thorac Oncol. 2016 Feb;11(2):142-54
pubmed: 26811225
J Thorac Oncol. 2018 Aug;13(8):1189-1203
pubmed: 29723687
Nat Genet. 2016 Apr;48(4):407-16
pubmed: 26928227
Lancet Oncol. 2019 Feb;20(2):239-253
pubmed: 30660609
J Thorac Oncol. 2018 May;13(5):606-623
pubmed: 29524617
Lung Cancer. 2018 Oct;124:95-101
pubmed: 30268487
Arch Pathol Lab Med. 2013 May;137(5):632-6
pubmed: 23627453
Cancer Discov. 2018 Dec;8(12):1548-1565
pubmed: 30322867
Int J Clin Oncol. 2016 Jun;21(3):523-30
pubmed: 26577445
Pathol Int. 2008 Feb;58(2):75-83
pubmed: 18199156
J Thorac Oncol. 2015 Nov;10(11):1634-41
pubmed: 26317916
JAMA. 2018 Sep 18;320(11):1101-1102
pubmed: 30178065
Lancet Oncol. 2015 Dec;16(16):1651-8
pubmed: 26538423
Hum Pathol. 2017 Sep;67:160-168
pubmed: 28782639
Arch Pathol Lab Med. 2020 Apr;144(4):446-456
pubmed: 31389715
Arch Pathol Lab Med. 2018 Jan;142(1):89-108
pubmed: 28686500
EBioMedicine. 2019 Oct;48:191-202
pubmed: 31648983
Am J Surg Pathol. 2017 Sep;41(9):1221-1225
pubmed: 28614203
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Hum Pathol. 2015 Nov;46(11):1670-8
pubmed: 26376834
Mod Pathol. 2010 Mar;23(3):470-9
pubmed: 20081811
Med Oncol. 2018 May 29;35(7):98
pubmed: 29845408
Mod Pathol. 2018 Apr;31(4):598-606
pubmed: 29327706
Arch Pathol Lab Med. 2016 Oct;140(10):1104-10
pubmed: 27031777
Am J Surg Pathol. 2015 Jul;39(7):977-82
pubmed: 25634745
Eur J Cancer. 2016 Apr;57:104-11
pubmed: 26916546
Arch Pathol Lab Med. 2018 Dec;142(12):1549-1553
pubmed: 30059257
Ultrastruct Pathol. 2009 Mar-Apr;33(2):52-60
pubmed: 19274581
J Thorac Oncol. 2018 Nov;13(11):1655-1667
pubmed: 30266660
Histopathology. 2000 Sep;37(3):224-31
pubmed: 10971698
Neural Comput. 2012 Aug;24(8):1967-2006
pubmed: 22509963
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007
Histopathology. 2009 May;54(6):667-76
pubmed: 19438742
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Francoise Galateau Salle (F)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France. Electronic address: francoise.galateau@lyon.unicancer.fr.

Nolwenn Le Stang (N)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.

Franck Tirode (F)

University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.

Pierre Courtiol (P)

OWKIN Paris, France.

Andrew G Nicholson (AG)

Department of Histopathology, Royal Brompton and Harefield NHS Foundation Trust and National Heart and Lung Institute, Imperial College, London, United Kingdom.

Ming-Sound Tsao (MS)

University Health Network, Princess Margaret Cancer Centre and University of Toronto, Department of Laboratory Medicine and Pathobiology, Toronto, Ontario, Canada.

Henry D Tazelaar (HD)

Mayo Clinic, Scottsdale, Arizona.

Andrew Churg (A)

Columbia University and Department of Pathology Vancouver, Canada.

Sanja Dacic (S)

FISH and Developmental Laboratory at the University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.

Victor Roggli (V)

Duke University Medical Center, Department of Pathology, Durham, North Carolina.

Daniel Pissaloux (D)

Department of BioPathology-FISH Laboratory, Centre Leon Berard Lyon, France.

Charles Maussion (C)

OWKIN Paris, France.

Matahi Moarii (M)

OWKIN Paris, France.

Mary Beth Beasley (MB)

Mount-Sinai Medical Center, Department of Pathology, New York, New York.

Hugues Begueret (H)

CHU Bordeaux, Haut Leveque Hospital, Department of Pathology, Bordeaux, France.

David B Chapel (DB)

University of Chicago, Department of Pathology, Chicago, Illinois.

Marie Christine Copin (MC)

University. Lille-CHU, Department of Pathology, Lille, France.

Allen R Gibbs (AR)

University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.

Sonja Klebe (S)

Department of Anatomical Pathology, Flinders University, Adelaide, Australia.

Sylvie Lantuejoul (S)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.

Kazuki Nabeshima (K)

Department of Pathology, Fukuoka University School of Medicine and Hospital, Fukuoka, Japan.

Jean-Michel Vignaud (JM)

CHU Nancy, INSERM, University of Lorraine, Lorraine, France.

Richard Attanoos (R)

University of Wales, Department of Cellular Pathology, Cardiff, United Kingdom.

Luka Brcic (L)

Department of Pathology, Graz, Austria.

Frederique Capron (F)

CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.

Lucian R Chirieac (LR)

Brigham and Women's Hospital, Boston, Massachusetts.

Francesca Damiola (F)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.

Ruth Sequeiros (R)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France.

Aurélie Cazes (A)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Bichat Department of Pathology, University Paris VII, Paris, France.

Diane Damotte (D)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Cochin-Hotel Dieu, Department of Pathology, Paris, France.

Armelle Foulet (A)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CH Le Mans, Department of Pathology, Pays de la Loire, France.

Sophie Giusiano-Courcambeck (S)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Hospital Nord, Marseille, University Aix-Marseille, Marseille, France.

Kenzo Hiroshima (K)

Tokyo Women's Medical University, Department of Pathology, Tokyo, Japan.

Veronique Hofman (V)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Mayo Clinic, Scottsdale, Arizona; CHU Nice, Department of Clinical and Experimental Pathology (LPCE), Nice, France.

Aliya N Husain (AN)

University of Chicago, Department of Pathology, Chicago, Illinois.

Keith Kerr (K)

Aberdeen Royal Infirmary, Department of Pathology, Aberdeen, Scotland.

Alberto Marchevsky (A)

Scotland Cedars-Sinai Medical Center, Department of Pathology, Los Angeles, California.

Severine Paindavoine (S)

University Claude Bernard Lyon, INSERM, CNRS, Research Cancer Center of Lyon, Centre Léon Bérard, Lyon, France.

Jean Michel Picquenot (JM)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, Henri Becquerel Centre, Rouen, France.

Isabelle Rouquette (I)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; IUCT-Oncopôle, Department of Pathology, Toulouse, France.

Christine Sagan (C)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; CHU Nantes, INSERM, Thorax Institute, Hôpital Laënnec CHU Nantes, Nantes, France.

Jennifer Sauter (J)

Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.

Francoise Thivolet (F)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.

Marie Brevet (M)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Hospices Civils, East Hospital Group, Department of Pathology, Lyon, France.

Philippe Rouvier (P)

CHU Pitié Salpétrière Paris, Department of Pathology, Paris, France.

William D Travis (WD)

Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York.

Gaetane Planchard (G)

MESOPATH, MESONAT, MESOBANK Department of BioPathology Centre Leon Berard, Lyon, France; Department of Pathology, CHU Caen, Caen, France.

Birgit Weynand (B)

UZ Leuven, Department of Pathology, Leuven, Belgium.

Thomas Clozel (T)

OWKIN Paris, France.

Gilles Wainrib (G)

OWKIN Paris, France.

Lynnette Fernandez-Cuesta (L)

Genetic Cancer Susceptibility Group International Agency for Research on Cancer World Health Organization, Lyon, France.

Jean-Claude Pairon (JC)

INSERM, UPEC, Faculty of Medicine and CHI Creteil, Professional Pathologies and Environment Department, IST-PE, Creteil, France.

Valerie Rusch (V)

Memorial Sloan Kettering Cancer Center, Department of Thoracic Surgery, New York, New York.

Nicolas Girard (N)

Department of Thoracic Oncology Institute Curie Paris, France and European Reference Network EURACAN, Centre Leon Berard, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH